Arcturus Therapeutics Holdings Inc. - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Arcturus Therapeutics Holdings Inc. on December 15, 2025, covering events occurring on December 11 and December 12, 2025. The filing addresses significant changes in executive leadership and board composition.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It is a current report focused on corporate governance and personnel changes rather than financial performance.
Material Changes
- Departure of CFO and Director: Andy Sassine, Chief Financial Officer and Board member, mutually agreed to end his employment effective December 31, 2025. He stepped down from the Board immediately on December 11, 2025. The Board size was reduced from nine to eight members.
- Appointment of Interim CFO: Joe Roberts, the Company's Controller since March 2024, was appointed Interim Principal Financial Officer and Interim Principal Accounting Officer on December 12, 2025.
- Severance and Compensation: Mr. Sassine is entitled to a lump sum severance of 12 months' base salary, potential bonus eligibility, COBRA coverage for up to 18 months, and immediate acceleration of all unvested stock options. Mr. Roberts' compensation remains under his 2018 agreement, with a base salary of $219,580 and up to 20% bonus eligibility.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The departure of Mr. Sassine was described as amicable with no disagreement regarding operations or policies. A seven-day revocation period applies to Mr. Sassine's Separation Agreement before benefits are finalized.
Investor Verification Checklist
- Verify the exact value of Mr. Sassine's base salary to calculate the 12-month severance lump sum.
- Confirm the number of unvested stock options held by Mr. Sassine that will accelerate immediately.
- Monitor the Company's announcement for a permanent CFO replacement following the interim appointment of Joe Roberts.
- Review the full text of the Separation Agreement (Exhibit 10.1) for any redacted confidential terms.